Escitalopram

Expert Opinion on Investigational Drugs

Volumn 11, Issue 10, 2002, Pages 1477-1486

  Burke, William J ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anxiety; Citalopram; Depression; Escitalopram; S citalopram

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESCITALOPRAM; PLACEBO; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANXIETY NEUROSIS; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION; ENANTIOMER; FATIGUE; FLU LIKE SYNDROME; HUMAN; INDIGESTION; INSOMNIA; ISOMERISM; MALE GENITAL SYSTEM DISEASE; NAUSEA; NONHUMAN; PANIC; RELAPSE; SHORT COURSE THERAPY; SOCIOPATHY; SOMNOLENCE; VERTIGO; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; DEPRESSION; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 0036798963     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.10.1477     Document Type: Article

References (45)

1. KESSLER RC, MCGONAGLE KA, ZHAO S et al: Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19.
2. LÉPINE JP, GASTPAR M, MENDLEWICZ J, TYLEE A: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Pychopharmacol, (1997) 12:19-29.
3. MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 349:1436-1442.
4. HIRSCHFELD RM: Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. Suppl. (2000) 403:35-38.
5. ZIMMERMAN M, MCDERMUT W, MATTIA JI: Frequency of anxiety disorders in outpatients with major depressive disorder. Am. J. Psychiatry (2000) 157:1337-1340.
6. LESPÉRANCE F, FRASURE-SMITH N, TALAJIC M, BOURASSA MG: Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation (2002) 105:1049-1053.
7. OKUN MS, WATTS RL: Depression associated with Parkinson's disease: clinical features and treatment. Neurology (2002) 58(4, Suppl. 1):S63-S70.
8. STARKSTEIN SE, PREZIOSI TJ, BERTIER ML, BOLDUC PL, MAYBERG HS, ROBINSON RG: Depression and cognitive impairment in Parkinson's disease. Brain (1989) 112:1141-1153.
9. ELLIOTT AJ, RUSSO J, ROY-BYRNE PP: The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen. Hosp. Psychiatry (2002) 24:43-47.
10. LESERMAN J, JACKSON ED, PETITTO JM et al: Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom. Med (1999) 61:397-406.
11. MENDLEWICZ J, LECRUBIER Y: Antidepressant selection: proceedings from a TCA/SSRI Consensus Conference. Acta Psychiat. Scand. Suppl. (2000) 403:5-8.
12. KELLER MB. Citaloprain therapy for depression: a review of 10 years of European experience and data from US clinical trials. J. Clin. Pychiatry (2000) 61:896-908.
13. HYTTEL J, BØGESØ KP, PERREGAARD J, SÁNCHEZ C: The pharmacological effect of citaloprain resides in the (S) - (+) enantiomer. J. Neural. Transm. (1992) 88:157-160.
14. SÁNCHEZ C, BRENNUM LT: Escitalopram is a highly selective and potent serotonin reuptake inhibitor. In vitro studies. Scandinavian College of Neuro-Pychopharmacology 1st Annual Meeting. Juan Les Pins, France (18-21 April 2001).
15. SÁNCHEZ C, HOGG S: The antidepressant effect of citalopram resides in the S-enantiomer (Lu 26-054). 55th Annual Scientific Conference of the Society of Biological Psychiatry, Chicago, IL, USA (11-13 May 2000).
16. BERGQVIST PBF, BRENNUM LT, SÁNCHEZ C: Escitalopram mediates citaloprain inhibition of DRN-5HT neural activity. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA (5-10 May 2001).
17. MØRK A, KREILGAARD M, SÁNCHEZ C, BRENNUM LT, WIBORG O: Escitalopram: a comparative study of in vitro and in vivo 5-HT uptake inhibitory activity. 23rd Congress of the Colligium Internationale Neuro-Psychopharmacolgicum, Montreal, Canada (23-27 June 2002).
18. OWENS MJ, KNIGHT DL, NEMEROFF CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry (2001) 50:345-350.
19. MITCHELL PJ, HOGG S: Escitalopram: behavioral model predicts antidepressant activity. 56th Annual Scientific Conference of Biological Psychiatry, New Orleans, LA, USA (3-5 May 2001).
20. PAPP M, SÁNCHEZ C: Escitalopram: potent and rapid in chronic mild stress model of depression. 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA (5-10 May 2001).
21. MONTGOMERY SA, LOFT H, SÁNCHEZ C, REINES EH, PAPP M: Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol. Toxicol. (2001) 88:282-286.
22. SÁNCHEZ C, PAPP M: The selective sigma2 ligand Lu-28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav. Pharmacol. (2000) 11:117-124.
23. SÁNCHEZ C: Escitalopram has potent anxiolytic effects in rodent anxiety models. 7th World Congress of Biological Psychiatry, Berlin, Germany (1-6 July 2001).
24. GUTIERREZ M, MENGEL H: Pharmacokinetics of escitalopram. 42nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, USA (10-13 June 2002).
25. DREWES P, TJIJSSEN I, MENGEL H, LARSEN F: A single-dose cross-over pharmacokinetic study comparing racemic citalopram (40 mg) with the S-enantiomer of citalopram (escitalopram, 20 mg) in healthy male subjects. 41st Annual Meeting of the New Clinical Drug Evaluation Unit, Phoenix, AZ, USA (28-31 May 2001).
26. ROCHAT B, AMEY M, BAUMANN P: Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse phase liquid chromatography. Ther. Drug Monit. (1995) 3:273-279.
27. VON MOLTKE LL, GREENBLATT DJ, GIANCARLO GM, GRANDA BW, HARMATZ JS, SHADER. RI: Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos. (2001) 8:1102-1109.
28. GUTIERREZ M, ROSENBERG J, ABRAMOWITZ W: Lack of a pharmacokinetic interaction between escitalopram and the CYP3A4 inhibitor ritonovir. 41st Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Phoenix, AZ, USA (23-31 May 2001).
29. BEERS MH, BERKOW R (Eds.): The Merck Manual (17th edition). Merck Research Laboratories, Whitehouse Station, NJ, USA (1999):2584.
30. WADE A, LEMMING OM, HEDEGAARD KB: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol. (2002) 17:95-102.
31. BURKE WJ, GERGEL I, BOSE A: Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J. Clin. Psychiatry (2002) 63:331-336.
32. TRIVEDI M, LEPOLA U: Flexible-dose experience with escitalopram in the treatment of major depressive disorder. Annual Meeting of the American College of Neurop pychopharmacology Waikoloa Village, HI, USA (9-13 December 2001).
33. GORMAN JM, KOROTZERA, SU G: Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrum (2002) 7(Suppl. 1):40-44.
34. FEIGHNER JP, OVERØ K: Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J. Clin. Psychiatry (1999) 60:824-830.
35. MENDELS J, KIEV A, FABREL LF: Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress. Anxiety (1999) 9:54-60.
36. RAPAPORT M, BOSE A, ZHENG H, KOROTZER A: Escitalopram prevents relapse of depressive episodes. Annual Meeting of The American College of Neuropsychopharmacology. Waikoloa Village, HI, USA (9-13 December 2001).
37. DAVIDSON J, BOSE A, SU G: Escitalopram in the treatment of generalized anxiety disorder. 42nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting. Boca Raton, FL, USA (10-13 June 2002).
38. STAHL SM, GERGEL I, LI D, KOROTZER A: Escitalopram in the treatment of panic disorder. 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA,USA (18-23 May 2002).
39. KASPER S, LOFT H, SMITH JR: Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA, USA (18-23 May 2002).
40. GERGEL I, HAKKARAINEN H, ZORNBERG G, KOROTZER A: Escitalopram is a well tolerated SSRL 155th Annual Meeting of the American Psychiatric Association. Philadelphia, PA, USA (18-23 May 2002).
41. ROSENBAUM JF, HAKKARAINEN H, SU G: Comparison of safety in placebo-controlled trials of escitalopram and citaloprain. 42nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting. Boca Raton, FL, USA (10-13 June 2002).
42. STAHL SM: Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. J. Clin. Psychiatry (1998) 59:642-643.
43. STAHL SM: Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol. Psychiatry (2000) 48:894-901.
44. BROWN WA, HARRISON W: Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J. Clin. Psychiatry (1995) 56:30-4.
45. THASE ME, FEIGHNER JP, LYDIARD RB: Citalopram treatment of fluoxetine nonresponders. J. Clin. Psychiatry (2001) 62:683-687.